| Dr William F Cathcart-rake, MD | |
|
511 S Santa Fe Ave, Salina, KS 67401-4145 | |
| (785) 827-7261 | |
| Not Available |
| Full Name | Dr William F Cathcart-rake |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Medical Oncology |
| Location | 511 S Santa Fe Ave, Salina, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003871757 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | 16278 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William F Cathcart-rake, MD 737 E Crawford St, Salina, KS 67401-5103 Ph: (785) 827-7261 | Dr William F Cathcart-rake, MD 511 S Santa Fe Ave, Salina, KS 67401-4145 Ph: (785) 827-7261 |
News Archive
Allscripts announced today that Legacy Health has selected the Allscripts Care Management solution for its six hospitals and two post-acute care facilities, helping to manage and coordinate care for the 90,000 patients it serves each year.
The drug Tysabri which was approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis in November 2004, was taken off the market in late February, after two cases of progressive multifocal leukoencephalopathy, or PML, appeared in patients given the drug during clinical trials.
As premium costs fell, enrollment rose – despite dire predictions from opponents of the 2010 health law that the overhaul would cause enrollment to drop while forcing the cost of premiums to increase.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.
› Verified 9 days ago
Peeran D. Sandhu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 511 S Santa Fe Ave, Suite 200, Salina, KS 67401 Phone: 785-452-4860 Fax: 785-452-4878 | |
Dr. William R Alsop, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 737 E Crawford St, Salina, KS 67401 Phone: 785-827-7261 | |
Dr. Carolyn Annette Hofer, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1410 E Iron Ave, Suite 1, Salina, KS 67401 Phone: 785-826-1580 | |
Jeffrey M. Geitz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 511 S Santa Fe Ave, Salina, KS 67401 Phone: 785-452-4860 Fax: 785-452-4878 | |
Dr. Kent B. Berquist, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S Santa Fe Ave, Suite 120, Salina, KS 67401 Phone: 785-452-7325 Fax: 785-452-6570 | |
Dr. Michael K. Lawrence, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 501 S Santa Fe Ave, Suite 200, Salina, KS 67401 Phone: 785-452-7269 Fax: 785-452-7566 |